Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

NuVasive Acquires Spine Implant Manufacturer ANC

RELATED NEWS
Trade NUVA now with 

Medical device maker NuVasive, Inc. (NUVA: Quote) said Monday that it has acquired ANC, LLC, a spine implant manufacturer based in Dayton, Ohio. for about $4.5 million.

NuVasive has been involved with the manufacturer since it was established in May 2010 as a manufacturing partner. The relationship expanded over the past 3 years, and ANC is currently one of NuVasive's significant implant suppliers.

NuVasive expects the deal be neutral to earnings in fiscal year 2013. Over the long term, however, the company expects vertical integration will provide opportunities to drive profitability improvements.

Alex Lukianov, NuVasive's Chairman and Chief Executive Officer, said, "We are very excited to welcome ANC's 65 member team into the NuVasive family. Over the past three years, we have been very impressed with ANC's progression as a quality manufacturer and their cultural fit with NuVasive. The facility will be designated NuVasive Manufacturing, LLC, and we look forward to expanding their capacity and systems as we grow together."

Click here to receive FREE breaking news email alerts for NuVasive, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Proctor and Gamble (PG) has sold two of its soap brands to European consumer products giant Unilever (UN). Cincinnati-based P&G says the sale includes the global Camay brand, the Zest brand outside of North America and its Talisman manufacturing plant in Mexico. The plant employs approximately... Dish Network is no longer carrying Fox News in yet another dispute for the television provider. Fox News, which changed the face of cable news with its ardent advocacy of conservative issues, went dark Sunday, replaced on Dish by The Blaze, Glen Beck's new right-leaning channel. Fox Business channel... Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.